Monday, November 04, 2024 8:18:32 AM
No doubt IMO that FDA is a believer in the efficacy of the hemostyp product!
https://finance.yahoo.com/news/united-health-products-provides-fda-130000023.html
"Notwithstanding the statistical conclusions of the clinical trial results, the FDA would like to see more data to confirm the safety and effectiveness of CelluSTAT in surgical procedures in the intestinal and thoracic organ space, where organ movement can impact the postoperative stability of a hemostat and where observation of postoperative rebleeding is more difficult. To address this concern, UHP has proposed to enroll a limited number of human subjects in a multi-site study as an extension of the original pivotal study, with patients undergoing surgical procedures within the organ space. Separately, the FDA confirmed that its earlier stated concern regarding use of CelluSTAT in vascular graft procedures had been adequately addressed."
“While we are pleased to confirm the path to resolving the list of deficiencies in our PMA application, we are disappointed that the strong results of our pivotal study and low incidence of adverse events were not sufficient to address the FDA’s specific concern regarding organ space applications of our device. The company will devote its resources to completing these additional surgical procedures efficiently and is confident that the results will reinforce the results of the existing study.”
I am buying more shares!!
$5-$10++
https://finance.yahoo.com/news/united-health-products-provides-fda-130000023.html
"Notwithstanding the statistical conclusions of the clinical trial results, the FDA would like to see more data to confirm the safety and effectiveness of CelluSTAT in surgical procedures in the intestinal and thoracic organ space, where organ movement can impact the postoperative stability of a hemostat and where observation of postoperative rebleeding is more difficult. To address this concern, UHP has proposed to enroll a limited number of human subjects in a multi-site study as an extension of the original pivotal study, with patients undergoing surgical procedures within the organ space. Separately, the FDA confirmed that its earlier stated concern regarding use of CelluSTAT in vascular graft procedures had been adequately addressed."
“While we are pleased to confirm the path to resolving the list of deficiencies in our PMA application, we are disappointed that the strong results of our pivotal study and low incidence of adverse events were not sufficient to address the FDA’s specific concern regarding organ space applications of our device. The company will devote its resources to completing these additional surgical procedures efficiently and is confident that the results will reinforce the results of the existing study.”
I am buying more shares!!
$5-$10++
Bullish
Recent UEEC News
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 08:49:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 02/02/2026 05:15:10 AM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 01/15/2026 10:01:16 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/22/2025 10:20:37 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 07:44:29 PM
- Life Sciences Virtual Investor Forum: Presentations Now Available for Online Viewing • GlobeNewswire Inc. • 09/18/2025 12:35:00 PM
- United Health Products to Present at the Life Sciences Virtual Investor Forum September 18th • GlobeNewswire Inc. • 09/16/2025 08:10:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 07:41:41 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/16/2025 01:53:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/08/2025 08:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/05/2025 08:15:27 PM
